Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.2B
70M shares
52-week range
$11.46 – $29.65
26% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
P/S (TTM)
1.1
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.
www.tandemdiabetes.comNo one on the platform currently holds TNDM.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 58,227 | $1.1M |
| Bridgewater Associatesas of 2024-12-31 | 7,378 | $265.8K |
| Execution date | Ratio |
|---|---|
| 2017-10-10 | 1-for-10reverse |
No one on the platform has traded TNDM yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 7.9% | 15.3% | ||||
| Profit Margin % | -20.2% | -14.0% | -31.7% | |||
| Free Cash Flow Margin % | -2.9% | 0.9% | -14.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.1B | +7.1% | $-0.67 | $-0.94–$-0.52 | — | 16 |
| 2027 | $1.2B | +12.4% | $0.14 | $-0.43–$0.58 | 114.7× | 16 |
| 2028 | $1.4B | +13.9% | $0.81 | $-0.06–$1.84 | 20.1× | 16 |
| 2029 | $1.5B | +9.5% | $1.33 | $1.29–$1.42 | 12.2× | 13 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.32 | $-0.31 | +3.3% |
| 2026-05-07 | $-0.46 | $-0.30 | +34.8% |
| 2026-02-19 | $-0.05 | $-0.01 | +80.0% |
| 2025-11-06 | $-0.31 | $-0.31 | +0.0% |
| 2025-08-06 | $-0.40 | $-0.48 | -20.0% |
| 2025-04-30 | $-0.60 | $-0.67 | -11.7% |
| 2025-02-26 | $-0.23 | $0.01 | +104.3% |
| 2024-11-06 | $-0.40 |
| $-0.35 |
| +12.5% |
| -0.13% |
| $855M |
| — |
| KODKodiak Sciences Inc. | $32.99 | -0.45% | $2.1B | — |
| NRIXNurix Therapeutics, Inc. | $24.83 | -2.70% | $2.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$TNDM The day Sheridan was named CEO in 2019, the stock was $69. It’s a miracle that a 70 year-old turns in a 75% decline over 7+ years and is still there.
View on StockTwits ↗
$SANA $ELDN $DXCM $PODD $TNDM It appears it is safe to assume Endo Axiom's Smart Oral insulin is now in human(s). Please Jesus let this work. This will ineffably transform the lives for us T1D's. Sana with sc451 is still on the horizon with Ph 1/2 to begin this year, IMHO the best potential option. Tego + Cadaveric islets is here RIGHT NOW with 12 out of 12 people (functionally) cured. T1D your days are numbered bitch. https://www.sydney.edu.au/news-opinion/news/2026/09/10/oral-insulin-drug-achieves-a-critical-milestone--.html
View on StockTwits ↗
$MODD $MODD $TNDM $PODD $MDT @Stef_Gee Lets debate MODD stock LETS TALK ANALYTICS LETS SETTLE THIS
View on StockTwits ↗$MODD my days on this app may be numbered. My recent post about @Stef_Gee was taken down I AM HERE FOR REAL STOCK ANALYSIS. But most people are too afraid to face the truth. Ready to debate $MODD with anyone $TNDM $PODD $MDT If anyone doubts modd is the next big thing i am ready to defend it. Respond.
View on StockTwits ↗
@BriOnH I bought $TNDM years ago at $3 and sold it at $110, good gain.
View on StockTwits ↗$SANA $ELDN $DXCM $PODD $TNDM Today is scheduled to be the first person ever dosed with Endo Axium Smart Oral Insulin. This could potentially radically change the lives for us T1D's, with even better stuff on the horizon. 🙏🏻🤞
View on StockTwits ↗
$TNDM Modular Medical secures contract with national U.S. PBM to offer Pivot tubeless insulin patch pump
View on StockTwits ↗
$MODD $ Modular Medical announced a contract with a national U.S. pharmacy benefit manager, expanding access to its Pivot™ tubeless patch-pump insulin delivery system as it prepares for its commercial launch. https://finance.yahoo.com/healthcare/articles/modular-medical-announces-contract-national-120000363.html #Diabetes #MedTech #InsulinPump $TNDM
View on StockTwits ↗$TNDM Modular Medical wins FDA clearance for software enhancements to Pivot tubeless insulin patch pump Cleared software expands Pivot pump functionality and customization ahead of planned fourth-quarter 2026 commercial launch.
View on StockTwits ↗
$TNDM Tandem Diabetes Care stock watch, strong day, attempting to rally off the 21.39 support area at https://www.stockconsultant.com/?TNDM Long Trade Target 1: 26.17 Profit: 18.9% Stop/Trailing Stop: 20.72 Loss: 5.9% P/L ratio: 3.2 : 1 - Good Target 2: 27.69 Profit: 25.8% P/L ratio: 4.4 : 1 - Excellent Extreme rally BULLISH [Positioning] Intermediate trend bullish, Uptrend. [Timing] Strong bullish 3 day candlestick pattern. [Timing] Good long trade quality BEARISH [Positioning] at resistance
View on StockTwits ↗
TUE 8/25: $TNDM – SELLING (ALL) P/L: -$803.14 -8.0% 10:06 AM – Getting out of TNDM this morning as the technical picture continues to deteriorate. Shares have been (1) posting a series of lower highs, (2) making new recent lows, and (3) trading with the 10 DMA now clearly rolling over. At the same time, my loss has reached roughly 8%, which is about as far as I generally allow a position to move against me under my risk-management guidelines. I’m exiting here and protecting capital. ULTRA Trader’s Tip: Respect Your Maximum Loss • Lower highs and new lows show that the stock is moving in the wrong direction. • A rolling-over 10 DMA confirms that short-term momentum is deteriorating. • Once a loss reaches your predetermined threshold, discipline matters more than hope—take the loss and move on. https://buyingbreakouts.com/tue-8-25-tndm-selling-all-p-l-803-14-8-0/
View on StockTwits ↗$MODD attention weaklings $PODD small people $MDT and the rest $TNDM Take a read
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.